Salix Pharmaceuticals, the gastrointestinal drug specialist, has snapped up fellow specialty drugmaker Santarus in a $2.6 billion all-cash buyout.
Bayer has taken another step toward fulfilling blockbuster ambitions for its eye drug Eylea. The German drugmaker asked European regulators to approve the vision-loss treatment for patients with diabetic macular edema. With diabetes on the rise all over the world, the new indication could offer long-term growth for the already fast-rising drug.
Shire is confirming reports that it plans to significantly cut back on its sizeable research operations in Basingstoke, U.K.--another setback for the country's research industry with Novartis axing more than 500 staffers and consultants in Horsham, following major blows from AstraZeneca and Pfizer.
After a big U.S. Justice Department settlement--after the speeches, the press releases, the commentary--attention invariably turns to the people who first blew the whistle. It's no different in the case of Johnson & Johnson, which this week announced a $2.2 billion settlement and misdemeanor plea in a longstanding probe of its Risperdal marketing.
With new trial data, Roche has more support for its thesis that Rituxan successor Gazyva beats the original. Combined with the chemo drug chlorambucil, Gazyva helped patients live a median of 26.7 months without their cancer progressing, compared with 15.2 months for the Rituxan-plus-chlorambucil combination.
Whether the Justice Department's off-label marketing enforcement actually deters bad behavior has been up for debate as one drugmaker after another agreed to pay hundreds of millions of dollars to settle federal investigations--some of them repeat offenders.
Chile-based CFR Pharmaceuticals has hit a wall in its quest to buy the South African drugmaker Adcock Ingram. Though leading Adcock shareholders had backed the $1.3 billion deal, the company's largest investor said no go.
The pharma industry led the layoffs charge during the month of October, accounting for 10,585 of the job cuts announced.
Vivus says it's laying off 20 staffers to cut its losses as the obesity drug Qsymia continues to flounder. Launched last year, Qsymia brought in just $6.4 million for the third quarter, far from the lofty sales projected as the drug neared FDA approval. And with the drug still struggling for a market foothold, analysts worry that Vivus will have a hard time attracting a partner that can apply its marketing savvy to the job.
As more and more baby boomers have signed on for testosterone testing--and, in turn, therapy--worries about the safety of testosterone-boosting drugs have grown. Now, a new study in the Journal of the American Medical Association puts some numbers to that concern.
Novartis and Pfizer are in the process of spinning off units. Abbott Laboratories set its pharma business free at the beginning of this year. Why wouldn't Merck decide to join the slim-down club?
Novartis has brought its job-cutting sword to the U.K., with plans to shutter an R&D site in Horsham. Up to 371 jobs are expected to disappear there. But that's not all. The Swiss drugmaker also plans to shed as many as 72 marketing and sales jobs.
U.K. officials are finally taking the wraps off their new drug-pricing plan. The pharma industry has been waiting for the update to go public--but branded drugmakers are likely to wish they could wait longer. Under the new 5-year agreement, drugmakers will suffer new spending caps beginning next year.
Shire shares spiked to an all-time high after the company revealed new data showing its ADHD drug Vyvanse was effective at treating binge eating disorder.
Regeneron once again beat expectations with its quarterly earnings. And once again, the company raised its forecast for Eylea, the vision-loss drug that's fueling much of its growth. But once again, Regeneron said that sales growth for Eylea was slowing down as patients use fewer doses.
Endo Health Solutions needs a shot in the arm, now that its lead drug Lidoderm faces generic competition. And Endo may have found just that. The has company inked a deal to buy Canada's Paladin Labs for $1.6 billion.
Last week, AstraZeneca admitted that the U.S. Justice Department is probing its controversial late-stage study of the blood thinner Brilinta. After a few days to digest that information, Bernstein's Tim Anderson has spelled out a worst-case scenario for the drug--and it's none too pretty. Worse, Brilinta is one of the products CEO Pascal Soriot hopes to transform into a growth engine for the company.
It looks as if Novartis has had enough of the animal kingdom. According to Bloomberg's sources, the Swiss drugmaker is leaning toward a sale or spinoff of its animal health unit as a first move toward a slimmer, more focused company.
The dust hasn't settled after ex-CEO Jeremy Levin's quick-and-dirty departure from Teva Pharmaceutical Industries. In fact, the dust just keeps getting stirred up as more details emerge about the company's inner workings. Meanwhile, the company is trying to get the wagon train moving again by asking the U.S. Supreme Court to block generic versions of its top-selling multiple sclerosis drug, Copaxone.
Johnson & Johnson has finally made a deal with the Justice Department. The Big Pharma giant agreed to pay $2.2 billion and plead guilty to a misdemeanor to wrap up a long-standing probe into its marketing of the antipsychotic drug Risperdal.